恆指曾漲逾300點 京東、阿里、百度、中升及百威亞太升3%至5%
恆指繼上周五回吐1.6%後,今早高開94點或0.6%,報16,046獲承接,曾升306點或1.9%高見16,258點遇阻,現報16,130點,回升177點或1.1%,總成交額399億元。此外,恆生科指曾升2.2%至3,256點後升幅略為回順,現報3,214,回升0.9%。
藍籌股普遍造好,內需股安踏(02020.HK)、李寧(02331.HK)、潤啤(00291.HK)、康師傅(00322.HK)、蒙牛(02319.HK)、中升(00881.HK)及百威亞太(01876.HK)升逾2%-5%。
藍籌物管股以碧服(06098.HK)及華潤萬象(01209.HK)高見5.86元及24.6元,現報5.64元及24.05元,回升1.8%及3%。
新經濟股以京東(09618.HK)、阿里(09988.HK)及百度(09888.HK)表現最好,股價高見94.9元、73.5元及107.2元,現報94.1元、73元及106.3元,回升3%左右。網易(09999.HK)高見161.4元,現報160元,回升1.7%。
金融股以招行(03968.HK)表現較堅挺,股價重越百天線,最高見29.85元,現報29.65元,續升2.4%。港交所(00388.HK)多升2.8%至250.8元遇阻,現報246.6元,回升1%;匯控(00005.HK)高見61.65元,現報61.45元,續升1.2%。
然而,中芯(00981.HK)、比亞迪(01211.HK)及聯想集團(00992.HK)逆市續跌3%-4%,報15.1元、184元及8.86元。
藥明生物(02269.HK)澄清首席執行官陳智勝從無為軍事醫學科學院或任何具有軍事背景機構工作及無贊助軍民融合項目,今早反覆受壓,現報24.2跌1.4%。藥明康德(02359.HK)重申業務發展不會對國家安全構成風險及澄清無贊助軍民融合項目,現報61.2元反覆跌5.3%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.